Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 8, 2007, Pages 3878-3887

  Miller, Emily C ^a   Capps, Byron E ^a   Sanghani, Ravi R ^a   Clemmons, David R ^a   Maile, Laura A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD47 ANTIGEN; GLUCOSE; MEMBRANE PROTEIN; PROTEIN SH2; PROTEIN SHC; PROTEIN TYROSINE PHOSPHATASE SHP 1; SOMATOMEDIN C; VITRONECTIN; VITRONECTIN RECEPTOR; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN RECEPTOR; LIGAND; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SRC HOMOLOGY 2 DOMAIN CONTAINING, TRANSFORMING PROTEIN 1; SRC HOMOLOGY 2 DOMAIN-CONTAINING, TRANSFORMING PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; HYPERGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RETINA CELL; SIGNAL TRANSDUCTION; ANIMAL; CATTLE; CELL CULTURE; CELL DIVISION; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PIGMENT EPITHELIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; CATTLE; CELL DIVISION; CELLS, CULTURED; DIABETIC RETINOPATHY; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; PHOSPHORYLATION; PIGMENT EPITHELIUM OF EYE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 34648828684     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0014     Document Type: Article

References (42)

1. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
2. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005;109:143-159.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390-1395.
5. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest. 2003;111:1835-1842.
6. Russell JW, Feldman EL. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res. 1999;31:90-96.
7. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
8. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996;2:529-533.
9. Wilkinson-Berka JL, Jones D, Taylor G, et al. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006;47:1600-1605.
10. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
11. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
12. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
13. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502.
14. Maile LA, Busby WH, Sitko K, et al. The heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol. 2006;20:405-411.
15. Maile LA, Busby WH, Sitko K, et al. IGF-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYD-MKTTC184 sequence of the β3 subunit of αVβ3. Mol Endocrinol. 2006;20:881-892.
16. Holmes DIR, Wahab NA, Mason RM. Identification of glucose-regulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Commun. 1997;238:179-184.
17. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun. 2000;267:257-261.
18. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem. 2004;279:34311-34322.
19. Stenina OI, Krukovets I, Wang K, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209-3215.
20. Takemoto M, Yokote K, Yamazaki M, et al. Enhanced expression of osteopontin by high glucose: involvement of osteopontin in diabetic macroangiopathy. Ann NY Acad Sci. 2000;902:357-363.
21. Yoon S, Gingras D, Bendayan M. Alterations of vitronectin and its receptor alpha(v) integrin in the rat renal glomerular wall during diabetes. Am J Kidney Dis. 2001;38:1298-1306.
22. Maile LA, Clemmons DR. Integrin-associated protein binding domain of thrombospondin-1 enhances insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Circ Res. 2003;93:925-931.
23. Maile LA, Imai Y, Clarke JB, Clemmons DR. Insulin-like growth factor I increases alpha Vbeta 3 affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane. J Biol Chem. 2002;277:1800-1805.
24. Zheng B, Clemmons DR. Blocking ligand occupancy of the alphaV-beta3 integrin inhibits insulin- like growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1998;95:11217-11222.
25. Ling Y, Maile LA, Clemmons DR. Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane associ-ation of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol Endocrinol. 2003;17:1824-1833.
26. Clemmons DR, Maile LA. Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology. 2003;144:1664-1670.
27. Ling Y, Maile LA, Lieskovska J, Badley-Clarke J, Clemmons DR. Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol Biol Cell. 2005;16:3353-3364.
28. Maile LA, Badley-Clarke J, Clemmons DR. The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Mol Biol Cell. 2003;14:3519-3528.
29. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
30. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46(suppl 2): S26-S30.
31. Meyer-Schwickerath R, Pfeiffer A, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
32. Sonksen PH, Russell-Jones D, Jones RH. Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res. 1993;40:68-79.
33. Dills DG, Moss SE, Klein R, Klein BE, Davis M. Is insulinlike growth factor I associated with diabetic retinopathy? Diabetes. 1990;39:191-195.
34. Dills DG, Moss SE, Klein R, Klein BE. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes. 1991;40:1725-1730.
35. Chavakis E, Riecke B, Lin J, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia. 2002;45:262-267.
36. Delannet M, Martin F, Bossy B, Cheresh DA, Reichardt LF, Duband JL. Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development. 1994;120:2687-2702.
37. Robbins SG, Brem RB, Wilson DJ, et al. Immunolocalization of integrins in proliferative retinal membranes. Invest Ophthalmol Vis Sci. 1994;35:3475-3485.
38. DeBosch BJ, Deo BK, Kumagai AK. Insulin-like growth factor-1 effects on bovine retinal endothelial cell glucose transport: role of MAP kinase. J Neurochem. 2002;81:728-734.
39. DeBosch BJ, Baur E, Deo BK, Hiraoka M, Kumagai AK. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. J Neurochem. 2001;77:1157-1167.
40. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA. 2001;98:5804-5808.
41. Weis SM, Lindquist JN, Barnes LA, et al. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood. 2007;109:1962-1970.
42. Schwartz MA, Brown EJ, Fazeli B. A 50-kDa integrin-associated protein is required for integrin-regulated calcium entry in endothelial cells. J Biol Chem. 1993;268:19931-19934.